There is a longer term government suppported (health outcome) agenda here to do with wanting doctors to better know what patients actually take, based on scripts filled etc (as opposed to what scripts issued), and better managing patients through conducting regular medication reviews.
So, over time, expect to see a lot more pharamacies involved and a platform connection with doctors - to enable their access to medication data (when permission given)... And expect to see a $ incentive, with what ultimately amounts to a ticket clip for MDR, accompanying medication reviews.
With Aptex and Sigma as investors in MDR, expect them to want to favour the continued development/evolution of MDR instead of potential competitors.
That's without the usual advertising etc revenue flows (to MDR) that will be able to be accessed as the number of active users climbs.
MDR is a better than average bet imo. Though there is execution risk, and the speed of the to-be-continued ramp-up is unknown, there appears to be some overall sensible-ness in what they are doing/offering.
MDR Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held
(20min delay)
